Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Options Exercise | $1.74M | +76.1K | +54.4% | $22.89 | 216K | Nov 11, 2021 | Direct | F1 |
transaction | PFE | Common Stock | Options Exercise | $1.77M | +64.8K | +30.01% | $27.34 | 281K | Nov 11, 2021 | Direct | F2 |
transaction | PFE | Common Stock | Options Exercise | $1.5M | +58.6K | +20.85% | $25.60 | 340K | Nov 11, 2021 | Direct | F1 |
transaction | PFE | Common Stock | Sale | -$107K | -2.12K | -0.63% | $50.34 | 337K | Nov 11, 2021 | Direct | |
transaction | PFE | Common Stock | Sale | -$116K | -2.3K | -0.68% | $50.32 | 335K | Nov 11, 2021 | Direct | |
transaction | PFE | Common Stock | Sale | -$161K | -3.2K | -0.95% | $50.29 | 332K | Nov 11, 2021 | Direct | |
transaction | PFE | Common Stock | Sale | -$171K | -3.4K | -1.02% | $50.31 | 328K | Nov 11, 2021 | Direct | |
transaction | PFE | Common Stock | Sale | -$263K | -5.23K | -1.59% | $50.29 | 323K | Nov 11, 2021 | Direct | |
transaction | PFE | Common Stock | Sale | -$338K | -6.71K | -2.08% | $50.33 | 317K | Nov 11, 2021 | Direct | |
transaction | PFE | Common Stock | Sale | -$1.85M | -36.7K | -11.6% | $50.28 | 280K | Nov 11, 2021 | Direct | |
holding | PFE | Common Stock | 1.8K | Nov 11, 2021 | By Rule 16b-3 Plan |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Phantom Stock Units | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities | -$2.4M | -47.8K | -40.14% | $50.18 | 71.3K | Nov 11, 2021 | Common Stock | 47.8K | Direct | F3, F4, F5 | |
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -154K | -100% | $0.00* | 0 | Nov 11, 2021 | Common Stock | 154K | $27.34 | Direct | |
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -146K | -100% | $0.00* | 0 | Nov 11, 2021 | Common Stock | 146K | $22.89 | Direct | |
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -127K | -100% | $0.00* | 0 | Nov 11, 2021 | Common Stock | 127K | $25.60 | Direct |
Id | Content |
---|---|
F1 | Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. |
F2 | Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. |
F3 | Each unit represents one phantom share of common stock. |
F4 | The reporting person diversified shares held in the Pfizer Inc. Deferred Compensation Plan ("Plan") pursuant to the Plan's diversification provision into an alternate investment option(s) under the Plan. |
F5 | The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |